Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term immunogenicity and late Ad26.ZEBOV booster study in previously vaccinated healthy volunteers
2017-004610-26Phase 2Unknown
- Sponsor
- University of Oxford
- Start
- Oct 2018
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zabdeno in Ebola virus disease (EVD), sponsored by University of Oxford. Status: unknown.
02
Drugs
zabdeno
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on 2017-004610-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004610-26.